Les Rencontres de Biarritz 2007 - THS 10

A NON-INVASIVE METHOD OF LIVER STIFFNESS MEASUREMENT WITH
ULTRASONIC TRANSIENT ELASTOGRAPHY. ACCEPTABILITY AND IMPACT
AMONG IN-TREATMENT SUBSTANCE DEPENDENT INDIVIDUALS.
RÉSUMÉ / ABSTRACT
BELTRAN V
AGUERRETXE-COLINA A
OUI B
DUBERNET J
DAULOUEDE J-P
AURIACOMBE M
Objective: To describe the acceptability of a non-invasive liver stiffness measurement for
patients attending addiction treatment within addiction based settings.
Methods: Liver stiffness was measured with ultrasonic transient elastography (UTE) using
FibroScan®, (Echosens, Paris, France). This is a 5-minute non-invasive and painless examination.
The results are immediately provided as a quantitative value (kPa). Subjects were recruited
in addiction treatment clinics and office-based-practice addiction treatment settings in the
metropolitan area of Bayonne, Aquitaine, France, in July 2006. General patient information
related to addiction treatment, liver medical history, acceptability of the procedure and its
impact on attitude regarding hepatic status was assessed by questionnaire.
Results: 94 patients (sex ratio M/F 3:1, aged 45 years SD= 9) were interviewed. 32% were in
opioid agonist pharmacotherapy for primary opiate dependence. 89% had knowledge of serostatus.
16% of these were HIV positive and 76% were HCV positive. All of those interviewed
accepted the UTE procedure. None reported discomfort or pain. UTE values ranged from 3.2
to 75 kPa. 65.5% were considered as having no fibrosis (below stage F2) and 1.3% as having
significant cirrhosis in need for treatment and many accepted liver related treatment for which
they had been reluctant. Subjects with hepatitis C showed significantly higher Fibroscan®
scores than those without (10.3 vs 6.8). 97% of subjects reported the procedure to be useful
and 99% of them would agree for another appointment for a Fibroscan® test.
Conclusion: With this high risk group of in-treatment substance users acceptability of fibrosis
assessment with a non-invasive procedure was very high, and many changed attitude regarding
possible hepatitis treatment as a consequence
MOTS CLÉS / KEYWORDS
Hépatite, foie, tolérance
Hepatitis, liver, tolerance
V. Beltran (2,1); A. Aguerretxe-Colina, (1,2); B. Oui (3); J. Dubernet (2); J-P. Daulouède (1,2); M.
Auriacombe, (2).
(1) Centre d’addictologie, BIZIA, Bayonne, France.
(2) Addiction Psychiatry, JE2358, INSERM IFR 99, Université Victor Segalen Bordeaux 2, Bordeaux, France.
(3) Service d’hépato-gastro-entérologie, CH Côte Basque, Bayonne, France
191